Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEAD Study tau PET tracer harmonization
2023-510508-31-01Phase 2Authorised
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Jun 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of florquinitau, flutemetamol and 18F-PI-2620 (9 arms), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoint: Standardized Uptake Value Ratio (SUVR) for tau PET tracers. Planned start Jun 2024; status: authorised.
02
Drugs
florquinitauflutemetamol18F-PI-2620
Beyond the preview
Go deeper on 2023-510508-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510508-31-01.